Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
August 10, 2023 08:00 ET
|
Daré Bioscience, Inc.
Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene® (hormone-free monthly contraception) –...
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings
August 09, 2023 08:00 ET
|
Daré Bioscience, Inc.
DARE-HRT1 Demonstrated Preliminary Treatment Efficacy for Both Vasomotor Symptoms (VMS) and Genitourinary Syndrome of Menopause (GSM) The North American Menopause Society (NAMS) Guidance on...
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
August 03, 2023 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
July 31, 2023 08:00 ET
|
Daré Bioscience, Inc.
Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and Treatment of Idiopathic Preterm Birth Currently no...
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
July 11, 2023 17:30 ET
|
Daré Bioscience, Inc.
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend,...
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
July 11, 2023 08:00 ET
|
Daré Bioscience, Inc.
Sildenafil Cream Demonstrated Statistically Significant Improvement in Sexual Desire, an Exploratory Endpoint; Improvements in Arousal Lubrication, Orgasm and Sexual Desire Seen in the Sildenafil...
Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
July 06, 2023 08:00 ET
|
Daré Bioscience, Inc.
Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT Webinar to include presentations by Daré management and key opinion leaders in reproductive and sexual medicine SAN DIEGO, July 06, 2023 ...
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
July 05, 2023 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO...
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women
June 21, 2023 08:00 ET
|
Daré Bioscience, Inc.
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly...
Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference
June 14, 2023 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...